Early palliative care in heart failure shows neutral effects across EF subtypes: an exploratory EPCHF secondary analysis.

Clin Res CardiolDec 16, 2025 (epub)
Clinical ResearchCardiologyOpen access

Mahmoud Balata, Asim Khan, Marwa Hassan et al.

✦ AI-curated · Sources linked

In 30 seconds

This exploratory secondary analysis of the multicentre randomised EPCHF trial assessed whether early integrated palliative care (EIPC) affected patient-reported outcomes differently by ejection-fraction subgroup in 205 patients with symptomatic heart failure. Over 12 months, quality-of-life, anxiety and symptom-intensity measures improved in both EIPC and standard-care groups, without significant between-group differences in either subgroup. Among patients with LVEF > 40%, EIPC was associated with better spiritual well-being than standard care (mean difference 3.47; 95% CI: 0.32 to 6.62; p = 0.031). Mortality and hospitalisation rates did not differ.

Key findings

  • KCCQ, HADS-anxiety and MIDOS measures improved over 12 months, with no significant EIPC–control differences in either EF subgroup.
  • In HFrEF, HADS-depression decreased in both EIPC (-1.37; 95% CI: -2.31 to -0.44; p = 0.004) and control (-1.99; 95% CI: -2.89 to -1.09; p < 0.001).
  • For LVEF > 40%, spiritual well-being improved with EIPC versus standard care (mean difference 3.47; 95% CI: 0.32 to 6.62; p = 0.031).
  • Mortality and hospitalisation rates did not differ between groups.

Why it matters

The analysis suggests that broad patient-reported benefits of early palliative care were not evident over standard care across EF subgroups, despite improvements over time in both groups. The isolated spiritual well-being result in patients with LVEF > 40% may point to differing supportive-care needs, but requires confirmation before being interpreted as a subgroup-specific benefit.

What to keep in mind

This was an exploratory secondary analysis, and the reported subgroup finding should be interpreted cautiously.

Source

Published in Clin Res Cardiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.